History
# Registration date Revision Id
2 2023-07-31, 1402/05/09 275144
1 2022-04-29, 1401/02/09 224324
Changes made to previous revision
  • Help:

    Red color represents old content. It may be empty showing addition in the new version.
    Green color represents new content. It may be empty showing deletion in the new version.

    Inline Side by side
    Added new contents, deleted old contents, contents that are not changed.
    New table contents New table contents
    Old table contents Old table contents
    Unchanged contents Unchanged contents
    Added new contents, contents that are not changed.
    Deleted old contents, contents that are not changed.
    Old table contents Old table contents
    Unchanged contents Unchanged contents
    New table contents New table contents
    Unchanged contents Unchanged contents
  • Protocol summary

    One group of patients will be given oral acetylcysteine 600 mg twice daily for 5 days and another group will be given 8 mg bromhexine tablets three times daily for 5 days. Referral, on day 7 and day 14, patients' oxygen levels and hospitalization and death are checked.
    One group of patients will be given oral acetylcysteine 600 mg twice daily for 5 days and another group will be given 8 mg bromhexine tablets three times daily and the control group will receive only the usual treatments prescribed to the other two groups. for 5 days. Referral, on day 7 and day 14, patients' oxygen levels and hospitalization and death are checked.
    .به گروهی از بیماران داروی استیل سیستئسین خوراکی 600 mg دو بار در روز به مدت 5 روز و به گروهی دیگر قرص برم هگزین 8 mg سه بار در روز به مدت 5 روز داده میشود و در روز مراجعه , روز7 و روز 14 سطح اکسیژن بیماران و بستری و مرگ آن ها بررسی میشود
    .به گروهی از بیماران داروی استیل سیستئسین خوراکی 600 mg دو بار در روز به مدت 5 روز و به گروهی دیگر قرص برم هگزین 8 mg سه بار در روز به مدت 5 روز داده میشود و گروه کنترل فقط درمان های معمول را دریافت خواهند کرد و در روز مراجعه , روز7 و روز 14 سطح اکسیژن بیماران و بستری و مرگ آن ها بررسی میشود
    This double-blind clinical trial is performed on 92 outpatients referred to Dibaj Municipal Services Center. The diagnosis of Covid-19 is debugged at the health service center and the patient enters the study after the test is confirmed. First, the blood oxygen level of the patients was measured with a pulse oximeter and from 92 patients, they were randomly assigned to group A and the rest to group B, and then to a group of patients taking oral acetylcysteine ​​600 mg twice daily. For 5 days, the other group is given 8 mg of bromhexine tablets three times a day for 5 days. Then, on day 7 and day 14, the patients are followed up and the patients' blood oxygen saturation level is measured and recorded with a pulse oximeter.
    This double-blind clinical trial is conducted on 225 outpatients at the Dibaj City Service Center. After the initial diagnosis of the covid-19 disease, according to the symptoms of the patients by the doctor, first of all, the pharynx and nose sample for RT-PCR test for The diagnosis of covid-19 is made in the health service center and after the positive test, the patient is included in the study. First, the blood oxygen level of the patients was measured with a pulse oximeter and patients were randomly divided into one of three groups. Patients are then asked to visit the clinic on the 7th and 14th days to check their oxygen levels.
    این کارآزمایی بالینی به صورت دو سو کور که بر روی 92بیمار سرپایی مراجعه کننده در مرکز خدمات شهری دیباج انجام میشود , بیماران بعد از تشخیص اولیه بیماری کووید_ 19 با توجه به علایم بیماران توسط پزشک , ابتدا نمونه حلق و بینی برای تست RT- PCR برای تشخیص کووید-19 در مرکز خدمات بهداشتی دیباج داده و پس ازمثبت شدن تست بیمار وارد مطالعه می‌شود. ابتدا سطح اکسیژن خون بیماران با پالس اکسی متر اندازه گیری شده و از 92 بیمار بـه طـور تصـادفي مجموعـهاي از آنـان را بـه گـروه A تخصـيص داده و باقيمانده را به گروه Bو سپس به گروهی از بیماران داروی استیل سیستئسین خوراکی 600 mg دو بار در روز به مدت 5 روز و به گروهی دیگر قرص برم هگزین 8 mg سه بار در روز به مدت 5 روز داده میشود .سپس بیماران در روز 7 و روز 14 بیماری پیگیری و سطح اشباع اکسیژن خون بیماران با پالس اکسی متر اندازه گیری وثبت می شود.
    این کارآزمایی بالینی به صورت دو سو کور که بر روی 225بیمار سرپایی مراجعه کننده در مرکز خدمات شهری دیباج انجام میشود , بیماران بعد از تشخیص اولیه بیماری کووید_ 19 با توجه به علایم بیماران توسط پزشک , ابتدا نمونه حلق و بینی برای تست RT- PCR برای تشخیص کووید-19 در مرکز خدمات بهداشتی دیباج داده و پس ازمثبت شدن تست بیمار وارد مطالعه می‌شود. ابتدا سطح اکسیژن خون بیماران با پالس اکسی متر اندازه گیری شده و بیماران بـه طـور تصـادفي به یکی از سه گروه تقسيم میشود. سپس از بیماران خواسته می شود در روزهای هفتم و چهاردهم به کلینیک مراجعه کنند تا سطح اکسیژن خود را بررسی کنند.
    Inclusion criteria include: • Adult patients aged 18 to 70 years referred to Dibaj Municipal Service Center • Outpatients with Covid-19 symptoms after positive Covid-19 RT-PCR test • Oxygen level 98-92% Exclusion criteria: • Pregnancy and lactation .Patients taking nitroglycerin.
    Inclusion criteria include: • Adult patients aged 18 to 80 years referred to Dibaj Municipal Service Center • Outpatients with Covid-19 symptoms after positive Covid-19 RT-PCR test • Oxygen level 98-92% Exclusion criteria: • Pregnancy and lactation .Patients taking nitroglycerin.
    معیارهاي ورود به مطالعه شامل: • بیماران بزرگسال با سن 18 تا 70 سال مراجعه کننده به مرکز خدمات شهری دیباج • بیماران مراجعه کننده به صورت سرپایی با علایم کووید-19 و پس از مثبت شدن تست RT-PCR Covid-19 • سطح اکسیژن 98-92 % معیارها خروج از مطالعه: • بارداری و شیردهی • بیمارانی که نیتروگلیسیرین استفاده می‌کنند.
    معیارهاي ورود به مطالعه شامل: • بیماران بزرگسال با سن 18 تا 80 سال مراجعه کننده به مرکز خدمات شهری دیباج • بیماران مراجعه کننده به صورت سرپایی با علایم کووید-19 و پس از مثبت شدن تست RT-PCR Covid-19 • سطح اکسیژن 98-92 % معیارها خروج از مطالعه: • بارداری و شیردهی • بیمارانی که نیتروگلیسیرین استفاده می‌کنند.
    This clinical trial is performed on outpatients Covid 19. One group of patients is given oral acetylcysteine 600 mg twice daily for 5 days and another group is given 8 mg bromhexine tablets three times daily for 5 days. On the day of referral, day 7 and day 14, patients' oxygen levels and their hospitalization and death are checked.
    This clinical trial is performed on outpatients Covid 19. One group of patients is given oral acetylcysteine 600 mg twice daily for 5 days and another group is given 8 mg bromhexine tablets three times daily for 5 days, The control group will receive only the usual treatments prescribed to the other two groups.
    این کارآزمایی بالینی بر روی بیماران سرپایی کووید 19 انجام میشود.به گروهی از بیماران داروی استیل سیستئسین خوراکی 600 mg دو بار در روز به مدت 5 روز و به گروهی دیگر قرص برم هگزین 8 mg سه بار در روز به مدت 5 روز داده میشود و در روز مراجعه , روز7 و روز 14 سطح اکسیژن بیماران و بستری و مرگ آن ها بررسی میشود.
    این کارآزمایی بالینی بر روی بیماران سرپایی کووید 19 انجام شده است. به یک گروه از بیماران استیل سیستئین خوراکی 600 میلی گرم دو بار در روز به مدت 5 روز و به گروه دیگر قرص 8 میلی گرم برومهکسین سه بار در روز به مدت 5 روز داده می شود. گروه کنترل فقط درمان های معمول را دریافت خواهند کرد که برای دو گروه دیگر تجویز می شود.
  • General information

    70
    80
    Not blinded
    Double blinded
    1
    1
    92
    225
    empty
    Due to re-judgment of the proposal
    empty
    به دلیل داوری مجدد پروپوزال
    Comparison of the effect of acetylcysteine and bromhexine on the rate of improvement and prevention of hospitalization in outpatients with Covid-19
    Evaluation of the efficacy of N-acetylcysteine and Bromhexine compared with Standard Care in Preventing Hospitalization of Outpatients with COVID-19: A double-blind randomized clinical trial
    مقایسه اثر دو داروی استیل سیستئین و برم هگزین بر روی میزان بهبود و جلوگیری از بستری در بیماران سرپایی مبتلا به کووید -19
    رزیابی اثربخشی N-استیل سیستئین و برومهگزین در مقایسه با مراقبت استاندارد در پیشگیری از بستری شدن بیماران سرپایی مبتلا به کووید-19: یک کارآزمایی بالینی تصادفی دوسوکور
    For this purpose, we will use the method of four random blocks (Block Randomization). For this purpose, we prepare four sheets of paper. On the two sheets, we write the letter I meaning "Intervention" and on the other two sheets we write the letter A meaning "Active Control". Mix the sheets together and place them in the desk drawer. When referring to any of the eligible patients, one of the sheets was randomly taken out, and based on this sheet, I or A was taken out and assigned to one of the two groups of intervention (NAC recipient) or comparison (bromhexine recipient). Will be given. It should be noted that the pulled-out sheets will not be returned to the drawer until all four sheets have been pulled out. After randomly pulling out all four sheets, all the sheets are returned to the drawer and the above procedure will be continued for the next four patients until the desired sample size (92 patients) is reached.
    We will use a six-block randomized method for patient allocation. Sheets will be prepared on which two sheets of letters "A", two sheets of "B" and two sheets of "C" will be written. These will be mixed up and placed in the desk drawer. When the patient is eligible, a card is randomly drawn and the patient is placed in groups "A", "B", "C". Notably, a particular card is not returned to the drawer until all six cards have been drawn once. This process of random allocation continues for the next six patients until the desired sample size of 225 patients is obtained.
    براي اين منظور از روش بلوک‌های تصادفی (Block Randomization) چهار تایی استفاده خواهيم نمود. براي اين منظور، چهار برگه كاغذي تهيه مي‌نماييم. بر روي دو برگه حرف I به معنی "Intervention" و بر روي دو برگه دیگر حرف Aبه معنی "Active Control" مي‌نويسيم. برگه‌ها را با هم مخلوط نموده و در كشو ميز قرار مي‌دهيم. با مراجعه‌ي هر يك از بيماران واجد شرايط، يكي از برگه‌ها را به صورت تصادفي بيرون كشيده و بر اساس این برگه بیرون کشیده شده I یا A باشد به يكي از دو گروه مداخله (دریافت کننده NAC) يا مقايسه (دریافت کننده برم هگزین) اختصاص داده خواهند شد. لازم به ذکر است برگه‌های بیرون کشیده شده تا زمانی هر چهار برگه بیرون کشیده نشده باشد به کشو برگردانده نخواهد شد. پس از بیرون کشیده شدن تصادفی هر چهار برگه، مجدداً همه برگه‌ها به کشو برگردانده شده و مجدداً عمل فوق برای چهار بیمار بعدی تا رسیدن به حجم نمونه مورد نظر (92 بيمار) ادامه داده خواهد شد.
    ما از یک روش تصادفی شش بلوکی برای تخصیص بیمار استفاده خواهیم کرد. برگه هایی تهیه خواهد شد که روی دو برگ حروف «الف»، دو ورق «ب» و دو ورق «ج» نوشته خواهد شد. اینها را به هم ریخته و در کشوی میز گذاشته خواهد شد. در زمان واجد شرایط بودن بیمار، یک برگه به صورت تصادفی کشیده شده و بیمار در گروه های «الف»، «ب»، «ج» قرارمیگیرد. قابل ذکر است، یک برگه خاص به کشو برگردانده نمی شود تا زمانی که هر شش برگ یک بار کشیده شده باشد. این فرآیند تخصیص تصادفی برای شش بیمار بعدی ادامه می ی تا اینکه حجم نمونه مورد نظر 225 بیمار به دست آمد.
    Both intervention and control groups will receive injectable drugs with the same appearance, which are marked with a code, and the patient and the examiner will be unaware of the type of drug used by the patients. Therefore, the study will be conducted in a double-blind manner.
    هر دو گروه مداخله و کنترل از داروهای تزریقی با ظاهری یکسان دریافت خواهند نمود که با کد مشخص شدهاند و بیمار و فرد معاینه کننده از نوع داروی مورد استفاده توسط بیماران بی اطلاع خواهند بود. بنابراین مطالعه به صورت دو سو کور اجرا خواهد شد.
  • Intervention groups

    #1
    empty
    Treatment - Drugs
    empty
    Control group: They will receive only the usual treatments prescribed for the other two groups. All patients received naproxen 250 mg twice daily for five days, famotidine 20 mg once daily for ten days, vitamin D 50,000 per week for four weeks, and vitamin C 1,000 mg daily.
    empty
    گروه کنترل: فقط درمان های معمولی را که برای دو گروه دیگر تجویز شده بود دریافت خواهند کرد. همه بیماران ناپروکسن 250 میلی گرم دو بار در روز به مدت پنج روز، فاموتیدین 20 میلی گرم یک بار در روز به مدت ده روز، ویتامین D 50000 در هفته به مدت چهار هفته و ویتامین C روزانه 1000 میلی گرم مصرف می کنند.
  • Recruitment centers

    #1
    Name of recruitment center - English: مرکز خدمات شهری دیباج
    Name of recruitment center - Persian: Dibaj Urban Health Services Center
    Full name of responsible person - English: محسن نوروزی
    Full name of responsible person - Persian: Mohsen norozi
    Street address - English: Kamalabad St., Dibaj Clinic
    Street address - Persian: خیابان کمال آباد , درمانگاه دیباج
    City - English: hamedan
    City - Persian: همدان
    Province: Hamadan
    Country: Iran (Islamic Republic of)
    Postal code: 6516768567
    Phone: +98 81 3833 1024
    Fax:
    Email: anahitaeslami1995@gmail.com
    Web page address:
    Name of recruitment center - English: Dibaj Urban Health Services Center
    Name of recruitment center - Persian: مرکز خدمات شهری دیباج
    Full name of responsible person - English: Mohsen Norozi
    Full name of responsible person - Persian: محسن نوروزی
    Street address - English: Kamalabad St., Dibaj Clinic
    Street address - Persian: خیابان کمال آباد , درمانگاه دیباج
    City - English: hamedan
    City - Persian: همدان
    Province: Hamadan
    Country: Iran (Islamic Republic of)
    Postal code: 6516768567
    Phone: +98 81 3833 1024
    Fax:
    Email: anahitaeslami1995@gmail.com
    Web page address:

Protocol summary

Study aim
Comparison of the effect of acetylcysteine and bromhexine on the improvement and prevention of hospitalization in outpatients
Design
One group of patients will be given oral acetylcysteine 600 mg twice daily for 5 days and another group will be given 8 mg bromhexine tablets three times daily and the control group will receive only the usual treatments prescribed to the other two groups. for 5 days. Referral, on day 7 and day 14, patients' oxygen levels and hospitalization and death are checked.
Settings and conduct
This double-blind clinical trial is conducted on 225 outpatients at the Dibaj City Service Center. After the initial diagnosis of the covid-19 disease, according to the symptoms of the patients by the doctor, first of all, the pharynx and nose sample for RT-PCR test for The diagnosis of covid-19 is made in the health service center and after the positive test, the patient is included in the study. First, the blood oxygen level of the patients was measured with a pulse oximeter and patients were randomly divided into one of three groups. Patients are then asked to visit the clinic on the 7th and 14th days to check their oxygen levels.
Participants/Inclusion and exclusion criteria
Inclusion criteria include: • Adult patients aged 18 to 80 years referred to Dibaj Municipal Service Center • Outpatients with Covid-19 symptoms after positive Covid-19 RT-PCR test • Oxygen level 98-92% Exclusion criteria: • Pregnancy and lactation .Patients taking nitroglycerin.
Intervention groups
This clinical trial is performed on outpatients Covid 19. One group of patients is given oral acetylcysteine 600 mg twice daily for 5 days and another group is given 8 mg bromhexine tablets three times daily for 5 days, The control group will receive only the usual treatments prescribed to the other two groups.
Main outcome variables
Duration of recovery, Duration of hospitalization, Death

General information

Reason for update
Due to re-judgment of the proposal
Acronym
IRCT registration information
IRCT registration number: IRCT20220302054167N1
Registration date: 2022-04-29, 1401/02/09
Registration timing: registered_while_recruiting

Last update: 2023-08-13, 1402/05/22
Update count: 1
Registration date
2022-04-29, 1401/02/09
Registrant information
Name
Anahita Eslami-ghayour
Name of organization / entity
Country
Iran (Islamic Republic of)
Phone
+98 81 3824 5383
Email address
anahitaeslami1995@gmail.com
Recruitment status
Recruitment complete
Funding source
Expected recruitment start date
2022-03-10, 1400/12/19
Expected recruitment end date
2022-05-09, 1401/02/19
Actual recruitment start date
empty
Actual recruitment end date
empty
Trial completion date
empty
Scientific title
Evaluation of the efficacy of N-acetylcysteine and Bromhexine compared with Standard Care in Preventing Hospitalization of Outpatients with COVID-19: A double-blind randomized clinical trial
Public title
The effect of acetylcysteine and bromhexine on the improvement and prevention of hospitalization in outpatients with Covid-19
Purpose
Prevention
Inclusion/Exclusion criteria
Inclusion criteria:
Outpatients with Covid-19 symptoms after positive Covid-19 RT-PCR test Oxygen level 98-92%
Exclusion criteria:
• Dissatisfaction of the patient or their relatives to participate in the study • Pregnancy and lactation Evidence of pulmonary involvement and the need for hospitalization or referral to an infectious disease specialist Prohibition of N-acetylcysteine and bromhexine as a history of allergy and anaphylactic shock
Age
From 18 years old to 80 years old
Gender
Both
Phase
3
Groups that have been masked
  • Participant
  • Investigator
Sample size
Target sample size: 225
Randomization (investigator's opinion)
Randomized
Randomization description
We will use a six-block randomized method for patient allocation. Sheets will be prepared on which two sheets of letters "A", two sheets of "B" and two sheets of "C" will be written. These will be mixed up and placed in the desk drawer. When the patient is eligible, a card is randomly drawn and the patient is placed in groups "A", "B", "C". Notably, a particular card is not returned to the drawer until all six cards have been drawn once. This process of random allocation continues for the next six patients until the desired sample size of 225 patients is obtained.
Blinding (investigator's opinion)
Double blinded
Blinding description
Both intervention and control groups will receive injectable drugs with the same appearance, which are marked with a code, and the patient and the examiner will be unaware of the type of drug used by the patients. Therefore, the study will be conducted in a double-blind manner.
Placebo
Not used
Assignment
Parallel
Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee
Name of ethics committee
Ethics Committee of Hamadan University of Medical Sciences
Street address
Research Ethics Committee, Vice Chancellor for Research and Technology, Hamadan University of Medical Sciences,Shahid Fahmideh Blvd.
City
Hamedan
Province
Hamadan
Postal code
۶۵۱۷۸۳۸۷۳۶
Approval date
2022-03-04, 1400/12/13
Ethics committee reference number
IR.UMSHA.REC.1400.957

Health conditions studied

1

Description of health condition studied
covid-19
ICD-10 code
U07.1
ICD-10 code description
COVID-19, virus identified

Primary outcomes

1

Description
blood Oxygen
Timepoint
At the beginning of the study (before the intervention) and 7, 14 days
Method of measurement
pulse oximeter

2

Description
Cough
Timepoint
At the beginning of the study (before the intervention) and 7, 14 days
Method of measurement
questionnaire

3

Description
Shortness of breath
Timepoint
At the beginning of the study (before the intervention) and 7, 14 days
Method of measurement
questionnaire

4

Description
Sore throat
Timepoint
At the beginning of the study (before the intervention) and 7, 14 days
Method of measurement
questionnaire

Secondary outcomes

1

Description
Time to recover from the desired symptoms
Timepoint
daily
Method of measurement
questionnaire

2

Description
Duration of hospitalization
Timepoint
At the beginning of the study (before the intervention) and 7, 14 days
Method of measurement
questionnaire

3

Description
Death
Timepoint
At the beginning of the study (before the intervention) and 7, 14 days
Method of measurement
questionnaire

Intervention groups

1

Description
Intervention group: The first group was a group of patients taking oral acetylcysteine(Hakim company) 600 mg twice daily for 5 days
Category
Treatment - Drugs

2

Description
Intervention group: The second method is for patients who take 8 mg of bromhexine tablets (Tolid Daroo) three times a day for 5 days.
Category
Treatment - Drugs

3

Description
Control group: They will receive only the usual treatments prescribed for the other two groups. All patients received naproxen 250 mg twice daily for five days, famotidine 20 mg once daily for ten days, vitamin D 50,000 per week for four weeks, and vitamin C 1,000 mg daily.
Category
Treatment - Drugs

Recruitment centers

1

Recruitment center
Name of recruitment center
Dibaj Urban Health Services Center
Full name of responsible person
Mohsen Norozi
Street address
Kamalabad St., Dibaj Clinic
City
hamedan
Province
Hamadan
Postal code
6516768567
Phone
+98 81 3833 1024
Email
anahitaeslami1995@gmail.com

Sponsors / Funding sources

1

Sponsor
Name of organization / entity
Hamedan University of Medical Sciences
Full name of responsible person
DR. Mhamad Khazaii
Street address
4th floor,University of Medical Sciences, Shahid Fahmideh St.,Research Square
City
Hamedan
Province
Hamadan
Postal code
۶۵۱۷۸۳۸۷۳۶
Phone
+98 81 3131 0000
Email
it.amoozesh@umsha.ac.ir
Web page address
Grant name
Grant code / Reference number
Is the source of funding the same sponsor organization/entity?
Yes
Title of funding source
Hamedan University of Medical Sciences
Proportion provided by this source
100
Public or private sector
Public
Domestic or foreign origin
Domestic
Category of foreign source of funding
empty
Country of origin
Type of organization providing the funding
Academic

Person responsible for general inquiries

Contact
Name of organization / entity
Hamedan University of Medical Sciences
Full name of responsible person
Anahita Eslami-Ghayour
Position
medical doctor
Latest degree
Medical doctor
Other areas of specialty/work
General Practitioner
Street address
No. 25, Jihad Alley, 18 meters from Fajr, Ostadan St.
City
Hamedan
Province
Hamadan
Postal code
6516866818
Phone
+98 81 3824 5383
Email
anahitaeslami1995@gmail.com

Person responsible for scientific inquiries

Contact
Name of organization / entity
Hamedan University of Medical Sciences
Full name of responsible person
Fariba keramat
Position
medical doctor
Latest degree
Specialist
Other areas of specialty/work
Infectious diseases
Street address
Pasteur Crossroads, Farshchian Educational and Medical Center, Hamedan
City
hamedan
Province
Hamadan
Postal code
6516866818
Phone
+98 81 3827 4184
Email
keramat@ umsha.ac.ir

Person responsible for updating data

Contact
Name of organization / entity
Hamedan University of Medical Sciences
Full name of responsible person
Fateme Shahbazi
Position
PhD student in epidemiology
Latest degree
Master
Other areas of specialty/work
Epidemiology
Street address
Research Square, Shahid Fahmideh St., hamedan University of Medical Sciences
City
Hamedan
Province
Hamadan
Postal code
۶۵۱۷۸۳۸۷۳۶
Phone
+98 81 3131 0000
Email
shahbazif2017@gmail.com

Sharing plan

Deidentified Individual Participant Data Set (IPD)
Yes - There is a plan to make this available
Study Protocol
Undecided - It is not yet known if there will be a plan to make this available
Statistical Analysis Plan
Not applicable
Informed Consent Form
Undecided - It is not yet known if there will be a plan to make this available
Clinical Study Report
Undecided - It is not yet known if there will be a plan to make this available
Analytic Code
Not applicable
Data Dictionary
Not applicable
Title and more details about the data/document
All data is potentially shareable after unidentifiable individuals
When the data will become available and for how long
Six months after the results were published
To whom data/document is available
Researchers working in academic institutions
Under which criteria data/document could be used
For further research purposes and analysis
From where data/document is obtainable
Anahita Eslami Ghayour, Hamedan University of medical science
What processes are involved for a request to access data/document
Official letter to researchers
Comments
Loading...